Vanda Pharmaceuticals stock posts positive HETLIOZ trial results

Published on 10/08/2026 at 06:51 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Vanda Pharmaceuticals stock has a Phase III HETLIOZ result after sleep onset shifted 42.5 minutes on September 29, 2026. Q2 revenue fell to USD 50.5 million.

VNDA, US9216591084, Illustration mit AI erstellt.

Vanda Pharmaceuticals stock (ISIN US9216591084) was last at USD 4.56 on Nasdaq on October 7, 2026 at 4:00 p.m. ET, up 0.88 percent from the prior close. The company had reported positive Phase III HETLIOZ results on September 29, 2026, giving investors a new clinical milestone as Vanda prepares a supplemental approval application.

HETLIOZ clears its trial endpoint

According to Finanznachrichten on September 29, 2026, HETLIOZ shifted sleep onset 42.5 minutes earlier in the Phase III treatment group, compared with 5.4 minutes for placebo. The resulting 37.1-minute difference met the primary endpoint with a p-value of 0.022.

The responder analysis added a second quantified signal: 60 percent of treated participants, or 12 of 20, advanced sleep timing by at least 30 minutes, compared with 15 percent, or 3 of 20, in the placebo group. Vanda said it plans to discuss the data with the FDA and file a supplemental New Drug Application for delayed sleep-wake phase disorder.

Fanapt growth offsets product pressure

Vanda's latest reported quarter shows why the pipeline result matters commercially. In Q2 2026, revenue was USD 50.5 million, down 4 percent from USD 52.6 million in Q2 2025, while net loss widened to USD 62.5 million, or USD 1.04 per diluted share, according to Yahoo Finance in the August 5, 2026 earnings transcript.

Fanapt net product sales provided the counterweight, rising 23 percent year over year to USD 36.0 million in Q2 2026. HETLIOZ sales fell 66 percent to USD 5.6 million, with management attributing the decline to generic competition and shipment timing; USD 7 million of orders shipped on June 29 were scheduled for recognition in Q3.

Analysts see a wide valuation gap

The analyst picture remains divided in magnitude but positive in direction. MarketBeat reported on October 2, 2026 that nine analysts held a Moderate Buy consensus, comprising six Buy, two Hold and one Sell ratings. The average 12-month price target was USD 13.08, while the highest and lowest targets were USD 20.00 and USD 7.50.

HC Wainwright reiterated a Buy rating with a USD 20.00 target on October 5, 2026, according to MarketBeat. Against the USD 4.56 Nasdaq price, that target lies 338.6 percent above the stock price, highlighting the gap between clinical optimism and current commercial execution.

Vanda stock remains near its yearly low

Vanda Pharmaceuticals stock was last at USD 4.56 on Nasdaq on October 7, 2026, with a session range of USD 4.44 to USD 4.64. Its 52-week range was USD 4.27 to USD 9.94, and market capitalization stood at USD 274.2 million on the same date.